甘草酸二铵肠溶胶囊预防抗结核药物性肝损伤疗效观察

Clinical observation of Diammonium Glycyrrhizinate Enteric-coated Capsules in preventing liver injury from anti-tuberculosis drugs

目的观察甘草酸二铵肠溶胶囊防治抗结核药物性肝损伤的疗效。方法将135例肺结核患者随机分为治疗组和对照组,均给予常规2HRZE/4HR化疗方案治疗;治疗组同时给予甘草酸二铵肠溶胶囊,对照组给予护肝片预防肝损伤。结果治疗组肝功能损害的发生率为4.35%,对照组为22.73%,两组具有统计学差异(P<0.05)。结论甘草酸二铵肠溶胶囊可预防抗结核药物性肝损伤。

Objective To observe the effects of Diammonium Glycyrrhizinate Enteric-coated Capsules（DGEC） on the prevention and treatment of anti-tuberculosis drug-induced liver injury. Methods One hundred and thirty-five tuberculosis cases were randomized into treatment and control groups, and were treated by regular 2HRZE/4HR; moreover, treatment group was given DGEC and control group was given ＂Hugan Tablets＂. Results The incidence of liver injury was 4.35% in the treatment group and 22.73% in the control group, with a difference between them（P 〈 0.05）. Conclusion Diammonium Glycyrrhizinate Enteric- coated Capsules is effective to prevent liver injury from anti-tubereulosis drugs.